PsilodexMedication × psilocybin
Your list , 0 items
Medication class

Opioids and opioid pain medications and psilocybin.

28 records in this group. 1 has published human data with psilocybin or another classic psychedelic; the rest draw on each medication's own pharmacology and label. State rules are summarized for Colorado, Oregon and New Mexico.

28Records
1With human data

Overview

Reviewed 2026-10-18

Opioid labels carry boxed warnings for life-threatening slowed breathing (respiratory depression), and for profound sedation, slowed or stopped breathing, coma and death when opioids are combined with benzodiazepines or other sedating drugs, including alcohol (tramadol prescribing information). Tramadol's label also reports serotonin syndrome with serotonergic drugs and seizures at doses within the labeled range (tramadol prescribing information). Tapentadol, meperidine, methadone and fentanyl also have serotonergic activity.

Opioids have almost no published data with psilocybin. In a supervised study, two adults taking buprenorphine-naloxone each had two psilocybin sessions; opioid craving and withdrawal measures did not change, and psilocybin's subjective effects were similar to earlier studies (Nicholas 2023). Two people are too few to show how often harms occur.

Stopping an opioid suddenly after regular use can cause withdrawal (tramadol prescribing information). This class also covers kratom, 7-hydroxymitragynine and illicit opioids; illicit supplies may contain fentanyl or nitazenes, and each record gives the details. Promethazine-codeine's Colorado status is unsettled because promethazine has antipsychotic-like activity; its record explains why. Opioid blockers such as naltrexone have their own page.

Psilodex presents published evidence and state psilocybin regulations for information only. It is not medical advice, a screening decision, or clearance to participate. Do not stop or change a medication without talking with the prescriber.

Also searched as opioid · opioids · opiate · narcotic

01 What the evidence covers

Best evidence available per medication
1Case reports
Case reports or online surveys
27No psilocybin data
No psilocybin data: no human data with psilocybin or another classic psychedelic; the text draws on the medication's own pharmacology and its label or reference facts

02 Each medication

A to Z
  • 7-Hydroxymitragynine (7-OH)Evidence: No psilocybin data

    Pain; Opioid withdrawal

    Its sedation may add to psilocybin's effects. Also, this concentrated kratom opioid can be stronger than morphine; FDA cites slowed breathing, seizures and withdrawal.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Acetaminophen–codeine · Tylenol #3Evidence: No psilocybin data

    Mild to moderate pain (when an opioid is appropriate)

    Its sedation and nausea may add to psilocybin's nausea. Stopping it suddenly after regular use can cause withdrawal.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Buprenorphine · Suboxone, Zubsolv, Sublocade, BrixadiEvidence: Case reports

    Opioid use disorder (opioid dependence)

    In two people on buprenorphine, psilocybin was tolerated without serious events. Stopping it suddenly after regular use can cause withdrawal.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • ButorphanolEvidence: No psilocybin data

    Pain severe enough to require an opioid when other treatments are inadequate; Before surgery or anesthesia, and as a supplement to balanced anesthesia (injection)

    Its label reports possible unpleasant dreamlike mental effects, which may add to psilocybin's. Stopping it suddenly after regular use can cause withdrawal.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • CodeineEvidence: No psilocybin data

    Mild to moderate pain when an opioid is appropriate

    Its sedation and nausea may add to psilocybin's nausea. Stopping it suddenly after regular use can cause withdrawal.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Codeine–guaifenesin · Mar-cof CG, Guaiatussin AC, Virtussin AC, Cheratussin ACEvidence: No psilocybin data

    Cough from minor throat and bronchial irritation (colds, inhaled irritants); Loosening phlegm (mucus) in the chest

    Codeine's sedation and nausea may add to psilocybin's nausea. Stopping it suddenly after regular use can cause withdrawal.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Fentanyl · DuragesicEvidence: No psilocybin data

    Severe long-term pain in opioid-tolerant patients

    This opioid can slow breathing and psilocybin does not; serotonin effects may add. Stopping it suddenly after regular use can cause withdrawal.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Heroin / illicit opioidsEvidence: No psilocybin data

    Other substances

    These opioids slow breathing and psilocybin does not; street supply often contains fentanyl. Stopping it suddenly after regular use can cause withdrawal.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Hydrocodone–acetaminophen · NorcoEvidence: No psilocybin data

    Pain severe enough to require an opioid

    Its sedation and nausea may add to psilocybin's; its breathing risk rises with other sedatives. Stopping it suddenly after regular use can cause withdrawal.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Hydromorphone · DilaudidEvidence: No psilocybin data

    Severe pain requiring an opioid when other treatments are inadequate

    It may add nausea to psilocybin's and causes sedation and slowed breathing, which psilocybin does not. Stopping it suddenly after regular use can cause withdrawal.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • KratomEvidence: No psilocybin data

    Pain; Opioid withdrawal symptoms

    Its opioid, stimulant and sedative effects may add to psilocybin's. Stopping it suddenly after regular use can cause withdrawal.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • LevorphanolEvidence: No psilocybin data

    Pain severe enough to require an opioid when other treatments are inadequate

    Its sedation and nausea may add to psilocybin's; it can slow breathing, which psilocybin does not. Stopping it suddenly after regular use can cause withdrawal.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Loperamide · Imodium, Imodium A-DEvidence: No psilocybin data

    Diarrhea, including travelers' diarrhea; Chronic diarrhea from inflammatory bowel disease

    Not studied with psilocybin; at labeled doses its brain opioid effects are minimal. Also, much higher doses have caused heart-rhythm problems and death.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Meperidine · DemerolEvidence: No psilocybin data

    Severe pain requiring an opioid; Pain control before and during surgery (preoperative medication, anesthesia support)

    Not studied with psilocybin; it has serotonin-boosting activity, so added serotonin effects are possible. Stopping it suddenly after regular use can cause withdrawal.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Methadone · MethadoseEvidence: No psilocybin data

    Severe, persistent pain requiring an opioid; Opioid use disorder (detoxification and maintenance treatment)

    Not studied with psilocybin; it is sedating and mildly serotonin-boosting, so added effects are possible. Stopping it suddenly after regular use can cause withdrawal.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Morphine · MS ContinEvidence: No psilocybin data

    Severe, persistent pain requiring an opioid when alternatives (including immediate-release opioids) are inadequate (extended-release tablets); Pain severe enough to require an opioid when alternatives are inadequate (injection)

    Its sedation and nausea may add to psilocybin's effects; slowed breathing is its own risk. Stopping it suddenly after regular use can cause withdrawal.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • NalbuphineEvidence: No psilocybin data

    Pain severe enough to require an opioid when other treatments are inadequate; Supplement to balanced anesthesia

    Not studied with psilocybin; it is sedating and its label reports hallucinations, so added effects are possible. Also, it can trigger opioid withdrawal.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Nitazenes (benzimidazole opioids)Evidence: No psilocybin data

    Other substances

    Not studied with psilocybin; these synthetic opioids, often hidden in counterfeit pills, slow breathing. Stopping them suddenly after regular use can cause withdrawal.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Oliceridine · OlinvykEvidence: No psilocybin data

    Acute pain severe enough to require an intravenous opioid when other treatments are inadequate (adults)

    Not studied with psilocybin; this hospital opioid sedates and slows breathing, which psilocybin does not. Stopping it suddenly after regular use can cause withdrawal.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Oxycodone · Roxicodone, OxyContinEvidence: No psilocybin data

    Pain severe enough to require an opioid when other treatments are inadequate (immediate-release); Severe, persistent pain needing long-term daily opioid treatment (extended-release)

    Its sedation and nausea may add to psilocybin's effects; slowed breathing is its own risk. Stopping it suddenly after regular use can cause withdrawal.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Oxycodone–acetaminophen · PercocetEvidence: No psilocybin data

    Pain severe enough to require an opioid when other treatments are inadequate

    Its sedation and nausea may add to psilocybin's effects; slowed breathing is its own risk. Stopping it suddenly after regular use can cause withdrawal.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • OxymorphoneEvidence: No psilocybin data

    Acute pain severe enough to require an opioid when other treatments are inadequate (immediate-release); Severe, persistent pain needing an opioid that other options cannot treat (extended-release)

    Its sedation and nausea may add to psilocybin's effects; slowed breathing is its own risk. Stopping it suddenly after regular use can cause withdrawal.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Pentazocine (with naloxone)Evidence: No psilocybin data

    Pain severe enough to require an opioid when other treatments are inadequate

    Not studied with psilocybin. Its label reports hallucinations and raised blood pressure, so added effects on perception and blood pressure are possible.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Promethazine-codeine ("lean")Evidence: No psilocybin data

    Cough and upper respiratory symptoms from allergies or the common cold (adults 18+)

    Not studied with psilocybin; with other sedatives, it can cause deep sedation and slowed breathing. Stopping it suddenly after regular use can cause withdrawal.

    CO: unsettled · OR: not mentioned in rule · NM: rules not final

  • SufentanilEvidence: No psilocybin data

    Analgesic adjunct in balanced general anesthesia (intubated, ventilated patients); Primary anesthetic for induction and maintenance of anesthesia

    Not studied with psilocybin. Psilocybin does not slow breathing, but this strong anesthesia opioid does. It is usually given only during monitored procedures.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Tapentadol · NucyntaEvidence: No psilocybin data

    Acute pain severe enough to require an opioid; Severe persistent pain requiring an opioid (extended-release)

    It may add serotonin effects to psilocybin and make seizures more likely. As an opioid it causes sedation and slowed breathing, which psilocybin does not.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Tianeptine · StablonEvidence: No psilocybin data

    Anxiety (promoted; not FDA-approved); Depression (promoted; not FDA-approved)

    Not studied with psilocybin; its serotonin effect is unclear. Also, it acts on opioid receptors, with misuse and dependence potential.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Tramadol · UltramEvidence: No psilocybin data

    Pain severe enough to require an opioid (adults)

    It may add serotonin effects to psilocybin or weaken it, and can cause seizures. As an opioid, it slows breathing; psilocybin does not.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

03 Properties the records flag

Records with each flag
28Opioid
27Sedating or CNS depressant
26Withdrawal or rebound if stopped abruptly
23Lowers seizure threshold or carries seizure risk
22Lowers blood pressure or causes orthostasis
21Serotonergic
4Liver injury
4Psychiatric reactions
4QT-prolonging
3Opioid blocker
3Raises blood pressure or heart rate
1Anticholinergic
1Dehydration or electrolyte risk
1Hypoglycemia risk
1Slows gastric emptying

Flags describe a medication's own properties, each cited in its record. A flag is not a finding about any combination. Definitions are on the Method page.

04 State rules

Official text governs
COColorado · final · checked 2026-10-24

No provision names these medications or this group. 1 unsettled.

Colorado rules 2.2(A)(6) and 2.2(A)(7) both address participants taking lithium or an antipsychotic, and the rule text does not state how the two fit together. The rule names “antipsychotic medications” without defining the term or limiting it by indication, so whether it covers this medication is unsettled; the regulator has not addressed this. This syrup contains promethazine, a phenothiazine (the chemical family of several antipsychotics) that blocks dopamine D2 receptors, but promethazine is approved for allergy, nausea and sedation, not for psychosis. Colorado rule 2.2(A)(6) states that Facilitator licensees may not provide natural medicine services to participants taking lithium or antipsychotic medications. Under 2.2(A)(7), services may proceed only after a referral from a licensed provider (MD, DO, APN, PA or clinical facilitator), medical clearance from the participant's provider, or a consultation and risk review with a provider licensed to diagnose and treat the condition identified as a risk factor; the Facilitator documents the consultation, and where it identifies heightened risk, the rule requires a safety plan and written informed consent.

Rule 2.2(A)(9): a facilitator must tell prospective participants in writing that anyone taking a psychotropic medication identified as a risk factor on the safety screen must meet one of the 2.2(A)(7) conditions. 2 of the 28 medications in this group are psychotropic; the rule applies when one is identified as a risk factor on a participant's screen.

OROregon · final · checked 2026-10-24

No provision names these medications or this group.

NMNew Mexico · pending · checked 2026-10-24

Rules not final; the proposed rules reviewed name no medication in this group.

05 Studies cited in this group

Records citing each
7Halman A, Kong G, Sarris J, Perkins D. Drug–drug interactions involving classic psychedelics: a systematic review. J Psychopharmacol 2024;38(1):3–18.
6Sarparast A, Thomas K, Malcolm B, Stauffer CS. Drug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review. Psychopharmacology 2022;239(6):1945–1976.
2Dahan A, Franko TS, Carroll JW, et al. Fact vs. fiction: naloxone in the treatment of opioid-induced respiratory depression in the current era of synthetic opioids. Front Public Health 2024;12:1346109.
1Nicholas CR, Horton DM, Malicki J, et al. Psilocybin for opioid use disorder in two adults stabilized on buprenorphine: a technical report on study modifications and preliminary findings. Psychedelic Med 2023;1(4):253–261.
1Roberts A, Korona-Bailey J, Mukhopadhyay S. Notes from the field: nitazene-related deaths — Tennessee, 2019–2021. MMWR 2022;71(37):1196–1197.
1Vandeputte MM, Krotulski AJ, Walther D, et al. Pharmacological evaluation and forensic case series of N-pyrrolidino etonitazene (etonitazepyne), a newly emerging 2-benzylbenzimidazole 'nitazene' synthetic opioid. Arch Toxicol 2022;96(6):1845–1863.

Related classes

Records reviewed 2026-10-03 to 2026-10-25. Each row summarizes one record; the full record, with every source, opens in the browser and is not sent to the server. All classes · Browse A–Z

AgreementPsilodex

Before you use Psilodex

Check each box to continue.

Your searches, your list and the medications you look up stay in this browser. We can't see them. Privacy · Emergency: 911 · Mental health crisis: call or text 988 · Poison Control: 1-800-222-1222

Terms version 2026-10-25